- Home
- YMAB vs ACIU Comparison
YMAB vs ACIU Comparison
Compare YMAB & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YMAB
- ACIU
- Stock Information
- Founded
- YMAB 2015
- ACIU 2003
- Country
- YMAB United States
- ACIU Switzerland
- Employees
- YMAB N/A
- ACIU N/A
- Industry
- YMAB Biotechnology: Pharmaceutical Preparations
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- YMAB Health Care
- ACIU Health Care
- Exchange
- YMAB Nasdaq
- ACIU Nasdaq
- Market Cap
- YMAB 218.4M
- ACIU 173.7M
- IPO Year
- YMAB 2018
- ACIU 2016
- Fundamental
- Price
- YMAB $4.04
- ACIU $1.66
- Analyst Decision
- YMAB Buy
- ACIU Strong Buy
- Analyst Count
- YMAB 11
- ACIU 2
- Target Price
- YMAB $18.73
- ACIU $10.00
- AVG Volume (30 Days)
- YMAB 204.4K
- ACIU 137.1K
- Earning Date
- YMAB 05-13-2025
- ACIU 04-30-2025
- Dividend Yield
- YMAB N/A
- ACIU N/A
- EPS Growth
- YMAB N/A
- ACIU N/A
- EPS
- YMAB N/A
- ACIU N/A
- Revenue
- YMAB $87,685,000.00
- ACIU $32,014,254.00
- Revenue This Year
- YMAB N/A
- ACIU N/A
- Revenue Next Year
- YMAB $18.83
- ACIU $676.94
- P/E Ratio
- YMAB N/A
- ACIU N/A
- Revenue Growth
- YMAB 3.38
- ACIU 91.20
- 52 Week Low
- YMAB $3.84
- ACIU $1.43
- 52 Week High
- YMAB $17.47
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- YMAB 42.87
- ACIU 44.86
- Support Level
- YMAB $4.02
- ACIU $1.55
- Resistance Level
- YMAB $4.60
- ACIU $1.79
- Average True Range (ATR)
- YMAB 0.32
- ACIU 0.10
- MACD
- YMAB -0.01
- ACIU 0.03
- Stochastic Oscillator
- YMAB 23.93
- ACIU 61.76
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.